

Erratum

Erratum to “Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients: 10-year results of a prospective randomised phase III study comparing carboplatin–cisplatin with cyclophosphamide–cisplatin” [European Journal of Cancer, 39 (2003) 1129–1140][☆]

Ch. Dittrich^{a,*}, P. Sevelde^b, H. Salzer^c, A. Obermair^d,
P. Speiser^d, G. Breitenecker^e, M. Schemper^f, A. Kaider^f,
on behalf of the Austrian Ovarian Cancer Study Group

^aLudwig Boltzmann-Institute for Applied Cancer Research, 3rd Medical Department with Oncology,
Kaiser Franz Josef-Spital, Kundratstrasse 3, 1100 Vienna, Austria

^bDepartment of Obstetrics and Gynecology, Krankenhaus Lainz, 1130 Vienna, Austria

^cDepartment of Gynecology and Obstetrics, Wilhelminenspital, 1160 Vienna, Austria

^dDepartment of Gynecology and Obstetrics, Vienna University, 1090 Vienna, Austria

^eDepartment of Pathology, Gynecopathologic Unit, Vienna University, 1090 Vienna, Austria

^fDepartment of Medical Computer Sciences, Vienna University, 1090 Vienna, Austria

The Publisher regrets that some of the values in Table 2 were not correctly displayed. The correct table is shown below:

Table 2

Number of courses completed, application intervals and number of courses administered/cancelled

| Course | Carboplatin–cisplatin (<i>n</i> = 124) | | | | Cyclophosphamide–cisplatin (<i>n</i> = 123) | | | |
|--------------------------------|---|-------|----------------------|---------|--|-------|----------------------|---------|
| | Patients treated | | Days between courses | | Patients treated | | Days between courses | |
| | <i>n</i> | (%) | Median | 90%tile | <i>n</i> | (%) | Median | 90%tile |
| 1 | 118 | (95) | – | – | 120 | (98) | – | – |
| 2 | 114 | (92) | 31 | 42 | 115 | (93) | 29 | 40 |
| 3 | 108 | (87) | 29 | 42 | 113 | (92) | 29 | 36 |
| 4 | 102 | (82) | 33 | 43 | 108 | (88) | 29 | 42 |
| 5 | 88 | (71) | 32 | 47 | 97 | (79) | 33 | 49 |
| 6 | 80 | (65) | 34 | 42 | 88 | (72) | 30 | 41 |
| Courses | Patients (<i>n</i>) | (%) | Courses (<i>n</i>) | (%) | Patients (<i>n</i>) | (%) | Courses (<i>n</i>) | (%) |
| Planned | 124 | (100) | 744 | (100) | 123 | (100) | 738 | (100) |
| Cancelled ^a due to: | 38 | (31) | | | 32 | (26) | | |
| Toxicity | 17 | | | 52 | 14 | | | 36 |
| PD + NC | 12 | | | 27 | 12 | | | 30 |
| Refusal | 12 | | | 56 | 9 | | | 42 |
| Administered | 80 | (65) | 610 | (82) | 88 | (72) | 641 | (87) |

PD, progressive disease; NC, no change.

^a One or more reasons for cancellation in a single patient simultaneously.

[☆] DOI of original article: 10.1016/S0959-8049(03)00152-7

* Corresponding author. Tel.: +43-1-60191-2303 or 2301; fax: +43-1-60191-2329.

E-mail address: christian.dittrich@wienkav.at (C. Dittrich).